SAMSUNG-SEMICONDUCTOR
15.9.2020 11:02:12 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced four new Samsung ISOCELL image sensors for its 0.7 micrometer (μm)-pixel product lineup; 108-megapixel (Mp) ISOCELL HM2, 64Mp ISOCELL GW3, 48Mp ISOCELL GM5 and 32Mp ISOCELL JD1. With the new 0.7μm ISOCELL technology, Samsung plans to expand the ultra-high-resolution offerings to mainstream smartphones.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005521/en/
“Samsung continues to pioneer innovations, such as ISOCELL Plus and Smart ISO, to deliver more pixels in a smaller package,” said Yongin Park, executive vice president of the sensor business at Samsung Electronics. “Last year, Samsung introduced the industry’s first 0.7μm-pixel image sensor and the first 108Mp sensors. Now we are bringing more of the advanced pixel technologies to mobile cameras in a variety of options that will enable high-resolution images and sleeker designs in a wider selection of tomorrow’s mobile devices.”
For ultra-high-resolution image sensors, even a mere 0.1μm-difference per pixel can have a significant impact on the overall size of the sensor as well as the height of the camera module. With pixels at 0.7μm, Samsung’s newest image sensors are up to 15-percent smaller than the 0.8μm sensors of the same resolution and reduce the height of the camera module by up to 10 percent. Smaller form factors give smartphone manufacturers more flexibility, such as added features or more streamlined designs, when developing their next-generation devices.
To collect an ample amount of light and increase the full well capacity despite the minute pixel sizes, Samsung has incorporated its advanced ISOCELL Plus and Smart-ISO technologies, especially optimized for 0.7μm. ISOCELL Plus retains the received light with a wall-like structure around the pixel while Smart-ISO makes full use of the incoming light by intelligently adjusting the ISO accordingly for optimal exposure.
In the latest 0.7μm products to be introduced later this year, Samsung will start rolling out an enhanced pixel technology, ISOCELL 2.0, which allows excellent performance despite the challenges with decreasing pixel sizes. The new technology further enhanced the wall structure between cells, resulting in added light sensitivity of up to 12 percent compared to the current ISOCELL Plus technology.
The New 0.7μm Lineup;
- ISOCELL HM2 is Samsung’s third 108Mp image sensor following the HMX and HM1. The new 108Mp-sensor is around 15-percent smaller than the 0.8μm-based predecessors, and reduces the height of the camera module by 10 percent. The HM2 features Super PD, a faster and more effective phase detecting auto focus solution, and like the HM1, comes with a nine-pixel binning technology as well as 3x lossless zoom.
- ISOCELL GW3 is a 64Mp-image sensor optimized for mainstream devices. Thanks to the smaller pixel size, the GW3’s optical size is nearly identical to that of Samsung’s 0.8μm 48Mp image sensor. In addition to Tetracell and Smart-ISO technologies that help the sensor take bright images with high color fidelity, the GW3 is ideal for active lifestyles, featuring gyro-based electronic image stabilization (EIS) for sharper still photos and steadier videos. The image sensor supports video recording at up to 4K resolution at 60 frames-per-second (fps).
- ISOCELL GM5 is a versatile 48Mp-image sensor designed for use in telescoping or ultra-wide angle cameras. When used as a 5x optical telescoping sensor for folded-zoom, the GM5 takes full advantage of the compact 0.7μm pixel size that minimizes the camera bulge. For ultra-wide shots, the GM5 supports high-speed full-HD recording at 480fps. The sensor also offers a staggered-HDR feature, a faster and more power-efficient HDR technology that expedites image processing by sending a readout of long, medium, and short exposures of each row of pixels respectively to the mobile processor. As the readout is performed based on Tetracell’s 1.4μm two-by-two pixels, rather than at the individual 0.7μm-pixel level, staggered-HDR can provide brighter and clearer images with less noise.
- ISOCELL JD1 is the industry’s smallest 32Mp-image sensor at 1/3.14-inches, making it an ideal solution for smartphones with bezel-less displays that incorporate a hole-in-active-area or motorized pop-up mechanism for the front-facing camera. Even with 32-million pixels to capture a highly detailed selfie, the camera sits comfortably under the display as the height of the sensor’s camera module is comparable to those of 0.9μm 20Mp or 1.0μm 16Mp sensors. Like the GM5, the JD1 is also the one the first ISOCELL image sensors to offer staggered-HDR.
Samsung ISOCELL HM2, GW3 and JD1 are currently in mass production, and the company is sampling GM5.
# # #
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
# # #
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005521/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
